# Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

> **NCT06036836** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 163 (actual)

## Conditions studied

- Solid Tumor
- Cutaneous Squamous Cell Carcinoma
- Endometrial Cancer

## Interventions

- **BIOLOGICAL:** favezelimab/pembrolizumab
- **BIOLOGICAL:** pembrolizumab
- **DRUG:** lenvatinib

## Key facts

- **NCT ID:** NCT06036836
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-29
- **Primary completion:** 2026-03-12
- **Final completion:** 2026-03-12
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06036836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06036836, "Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06036836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*